ALX Oncology Holdings, Inc. (ALXO)

ALX Oncology Holdings, Inc. stock price has increased approximately 93.81% in the past six months. Key events impacting the stock include the Third Quarter 2025 Financial Results, presentation at the 44th Annual J.P. Morgan Healthcare Conference, pricing of an underwritten offering, and the Fourth Quarter and Full Year 2025 Financial Results. Analysts have issued a "Moderate Buy" consensus rating for ALXO.

There is no demand seasonality for ALX Oncology Holdings, Inc.'s products or services. Demand is primarily driven by clinical trial progression, regulatory approvals, and the prevalence of specific cancer indications.

ALX Oncology Holdings, Inc. is a clinical-stage immuno-oncology company focused on developing and commercializing next-generation cancer therapies. Their lead product candidate, Evorpacept, is in Phase 1 and 2 clinical trials as a combination therapy for various indications, including Gastric/GEJ cancer. Another product candidate is ALX2004, an EGFR-targeted antibody-drug conjugate, which is in a Phase 1 clinical trial for treating solid tumors.

ALX Oncology Holdings, Inc. is headquartered in South San Francisco, California, and conducts clinical studies primarily in the United States, with international collaborations for patient enrollment.

ALX Oncology Holdings, Inc. generally maintains a positive brand reputation within the scientific and investment communities, recognized for its focus on novel cancer treatment approaches and scientific advancement. Analyst ratings reflect this, with a consensus of "Moderate Buy" from Wall Street equities research analysts over the past year. The company did report a net loss in Q1 2025, exceeding consensus estimates, and made a decision to discontinue evaluations of its candidate Evorpacept for head and neck squamous cell carcinoma and bladder cancer due to subpar clinical data.

The ownership structure of ALX Oncology Holdings (ALXO) stock is a mix of institutional, retail, and individual investors. Approximately 53.87% of the company's stock is held by institutional shareholders. Insiders own about 27.04% of the stock. Retail investors hold approximately 19.09% of the stock.